Vaxart (OTCMKTS:VXRT) Announces Quarterly Earnings Results

Vaxart (OTCMKTS:VXRT) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.06, Zacks reports. Vaxart had a return on equity of 61.43% and a net margin of 14.51%.

Vaxart Stock Down 3.3%

Shares of VXRT traded down $0.02 during mid-day trading on Thursday, reaching $0.57. The company’s stock had a trading volume of 181,566 shares, compared to its average volume of 304,882. The company has a market cap of $138.42 million, a price-to-earnings ratio of 3.80 and a beta of 1.10. The business has a fifty day moving average of $0.56 and a 200 day moving average of $0.63. Vaxart has a 1 year low of $0.30 and a 1 year high of $0.84.

Hedge Funds Weigh In On Vaxart

A number of large investors have recently made changes to their positions in VXRT. Goldman Sachs Group Inc. acquired a new stake in shares of Vaxart during the first quarter worth approximately $31,000. Creative Planning acquired a new position in Vaxart in the 2nd quarter valued at approximately $33,000. Invesco Ltd. lifted its position in Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after buying an additional 70,568 shares in the last quarter. Raymond James Financial Inc. lifted its position in Vaxart by 16.9% in the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after buying an additional 34,075 shares in the last quarter. Finally, Jones Financial Companies Lllp lifted its position in Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after buying an additional 478,111 shares in the last quarter. Institutional investors and hedge funds own 18.05% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Vaxart to a “hold” rating in a research report on Thursday, July 9th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Vaxart presently has an average rating of “Hold”.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.